Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis ; volume:37 ; number:9 ; day:4 ; month:8 ; year:2020 ; pages:4033-4042 ; date:9.2020
Advances in therapy ; 37, Heft 9 (4.8.2020), 4033-4042, 9.2020
- Creator
-
Lampertico, Pietro
Mauss, Stefan
Persico, Marcello
Barclay, Stephen T.
Marx, Steven
Lohmann, Kristina
Bondin, Mark
Zhang, ZhenZhen
Marra, Fiona
Belperio, Pamela S.
Wedemeyer, Heiner
Flamm, Steven
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-020-01449-0
- URN
-
urn:nbn:de:101:1-2020112701575439543947
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lampertico, Pietro
- Mauss, Stefan
- Persico, Marcello
- Barclay, Stephen T.
- Marx, Steven
- Lohmann, Kristina
- Bondin, Mark
- Zhang, ZhenZhen
- Marra, Fiona
- Belperio, Pamela S.
- Wedemeyer, Heiner
- Flamm, Steven
- SpringerLink (Online service)
Other Objects (12)
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Response of treatment-naive brain metastases to stereotactic radiosurgery
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
ICG-r15 predicts esophageal varices in compensated liver cirrhosis: a noninvasive approach
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Response of treatment-naive brain metastases to stereotactic radiosurgery
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
ICG-r15 predicts esophageal varices in compensated liver cirrhosis: a noninvasive approach
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Response of treatment-naive brain metastases to stereotactic radiosurgery
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression